(News Bulletin 247) – Poxel today publishes its cash position, its turnover and provides an overview of its activities for the first quarter ended March 31, 2023.

The biopharmaceutical company achieved a turnover of 0.449 million euros for the quarter ended March 31, 2023, compared to 0.32 million euros for the corresponding period in 2022.

Total cash and cash equivalents was €10.6 million ($11.6 million), compared to €13.1 million ($14.0 million) as of December 31, 2022 .

Net financial debt amounted to €34.8 million as of March 31, 2023, compared to €29.5 million as of December 31, 2022.

Sumitomo Pharma’s fiscal 2022 TWYMEEG sales in Japan are more than 20% higher than Sumitomo Pharma’s forecast, which forecasts TWYMEEG’s fiscal 2023 sales growth of 90% year-on-year former.

The Company is actively seeking additional funding to initiate phase II proof-of-concept (POC) studies in adrenoleukodystrophy (ALD).

“We have successfully restructured our debt and given ourselves greater financial flexibility,” said Thomas Kuhn, CEO of Poxel.

Copyright (c) 2023 News Bulletin 247. All rights reserved.